Twin to Twin Transfusion Syndrome – Complete Guide for Parents

Twin-to-twin transfusion syndrome (TTTS) is a serious complication of monochorionic twin pregnancies in which imbalanced blood flow through shared placental vessels threatens the lives of both fetuses. Without timely intervention, the condition can progress rapidly, but advances in fetal surgery have significantly improved outcomes for affected pregnancies.

TTTS occurs in approximately 10 to 15 percent of monochorionic diamniotic (MCDA) twin gestations, according to estimates from Johns Hopkins Medicine and the Twins Trust. The condition arises when arteriovenous anastomoses within a single shared placenta create a net transfer of blood from one twin — the donor — to the other, the recipient. The donor becomes hypovolemic and develops oligohydramnios, while the recipient becomes hypervolemic and develops polyhydramnios, placing both at risk of heart failure, preterm birth, and fetal death.

Early detection through routine ultrasound surveillance is critical. The Royal College of Obstetricians and Gynaecologists (RCOG) recommends that women with MCDA twins undergo ultrasound screening every two weeks starting at 16 weeks of gestation. Because TTTS can worsen rapidly, prompt recognition and referral to a fetal medicine center can make a substantial difference in prognosis.

What Is Twin-to-Twin Transfusion Syndrome (TTTS)?

TTTS is a rare but life-threatening pregnancy condition that specifically affects identical twins who share one placenta. The following overview summarizes the key characteristics of this syndrome.

Key insights about TTTS:

• TTTS is a progressive condition that can worsen rapidly; accurate staging is essential for prognosis and treatment decisions.
• Untreated severe TTTS (Stage III–IV) carries a high mortality rate, but with laser therapy, survival of at least one twin exceeds 70 percent.
• TTTS only affects monochorionic twins; dichorionic twins are not at risk because their placentas do not share vascular connections.
• Early detection via routine ultrasound screening in monochorionic pregnancies is key to timely intervention.
• Long-term outcomes for survivors are generally favorable, though some children may face neurodevelopmental or cardiac challenges.
• Support organizations such as the TTTS Foundation and Twins Trust offer resources and helplines for affected families.

How Is TTTS Diagnosed and Staged?

Diagnosis of TTTS relies on ultrasound criteria that are typically identifiable after 16 weeks of gestation. The key sonographic findings include oligohydramnios in the donor sac — defined as a deepest vertical pocket of 2 cm or less — and polyhydramnios in the recipient sac, defined as a deepest vertical pocket of 8 cm or more before 26 weeks or 10 cm or more after that point. Other signs include a visible bladder in the recipient twin and an absent or very small bladder in the donor, as well as discordant fetal growth, often defined as an estimated fetal weight difference of approximately 25 percent. Doppler studies may also show absent end-diastolic flow in the umbilical artery of the donor, which can indicate more severe disease. For a deeper dive into the classification and management of this condition, refer to the Twin-to-Twin Transfusion Syndrome (TTTS): Comprehensive Overview.

What Does TTTS Look Like on Ultrasound?

On radiology and ultrasound examination, the most striking feature is the marked discrepancy in amniotic fluid volume between the two sacs. The recipient twin is surrounded by excessive fluid, while the donor appears compressed within a very low–fluid environment — sometimes referred to as the stuck twin sign. Growth discordance, bladder size discrepancy, and Doppler abnormalities further support the diagnosis. These findings are the basis of the widely used Quintero staging system.

What Are the Quintero Stages of TTTS?

Developed by Dr. Ruben Quintero, this ultrasound-based staging system classifies TTTS into five progressive stages that predict prognosis and guide treatment decisions. Progression through stages can occur without intervention.

• Stage I: Oligo-polyhydramnios sequence is present. The donor has a deepest vertical pocket (DVP) of 2 cm or less; the recipient has a DVP of 8 cm or more. Both bladders are visible, and no Doppler abnormalities are detected.
• Stage II: The donor bladder is no longer visible. Critical Doppler changes are still absent.
• Stage III: Abnormal Doppler findings emerge — absent or reversed end-diastolic flow in the donor umbilical artery, absent or reversed a-wave in the ductus venosus of the recipient, or pulsatile umbilical vein flow.
• Stage IV: The recipient develops hydrops fetalis, evidenced by ascites, pleural or pericardial effusion, or skin edema.
• Stage V: Demise of one or both twins has occurred.

What Is Stage 2 TTTS?

Stage II TTTS is defined by the absence of a visible fetal bladder in the donor twin, in addition to the oligo-polyhydramnios sequence. At this stage, Doppler studies remain normal — no critical flow abnormalities are present. The progression from Stage I to Stage II signals worsening hypovolemia and renal hypoperfusion in the donor. Stage II is generally considered an indication for intervention, typically fetoscopic laser ablation.

What Are the Treatment Options for TTTS?

Several treatment strategies exist for TTTS, and the choice depends primarily on the Quintero stage at diagnosis, gestational age, and the clinical picture. Fetoscopic laser surgery is the gold-standard therapy for Stages II through IV and for selected Stage I cases. Alternatives include amnioreduction and, in rare situations, selective fetocide or expectant management.

What Is Fetoscopic Laser Ablation?

Fetoscopic laser photocoagulation, also known as selective laser ablation of placental anastomoses, is performed under maternal anesthesia. A thin fetoscope is inserted through the maternal abdomen into the amniotic cavity of the recipient twin, allowing the surgeon to identify and coagulate the abnormal vascular connections on the placental surface. The goal is to restore a balanced distribution of blood flow between the two fetuses. The procedure is ideally performed between 16 and 26 weeks of gestation, with better outcomes associated with earlier intervention. According to meta-analyses and Cochrane reviews, laser ablation yields double survival rates of 60 to 70 percent.

What Is Amnioreduction and When Is It Used?

Amnioreduction involves the ultrasound-guided removal of excess amniotic fluid from the recipient sac, which can relieve maternal discomfort and reduce the risk of preterm labor or rupture of membranes. It is primarily used for Stage I disease, for pregnancies presenting before 26 weeks when laser is not immediately available, or as a palliative measure when laser has failed or is not feasible. However, amnioreduction does not address the underlying vascular cause of TTTS, and compared with laser therapy, it is associated with higher morbidity and less favorable neurodevelopmental outcomes.

What Do RCOG Guidelines Recommend for TTTS?

The RCOG Green-top Guideline No. 51, originally published in 2016 and reaffirmed thereafter, provides a comprehensive framework for managing TTTS. It mandates ultrasound surveillance of all MCDA twin pregnancies from 16 weeks onward, defines the indications for laser therapy versus amnioreduction, and stresses the importance of multidisciplinary care. The guideline also recommends that women diagnosed with TTTS be referred urgently to a fetal therapy center with proven laser experience. The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) similarly endorses cardiac assessment and mandatory referral to specialized laser centers.

What Is the Survival Rate and Prognosis for TTTS?

Survival rates for TTTS vary considerably depending on the Quintero stage at diagnosis, the treatment modality used, and the gestational age at intervention. Data from meta-analyses and systematic reviews — including a 2023 Cochrane update (PMC10816955) and a large meta-analysis (PubMed 32330342) — provide stage-specific survival estimates that help guide clinical decision-making and counseling.

What Is the Survival Rate by Stage?

The table below summarizes survival outcomes by Quintero stage based on published data from fetal therapy centers worldwide. Laser therapy consistently yields higher survival and lower neurological impairment compared with amnioreduction.

Overall, laser therapy yields double survival in 70 to 86 percent of cases at six months, compared with 38 to 64 percent for amnioreduction. The rate of at least one survivor ranges from 76 to 80 percent for laser versus 51 to 78 percent for amnioreduction. Gestational age at birth is similar across Stages I through III — typically 32 to 34 weeks — but drops below 30 weeks in Stages IV and V.

What Happens After Birth for TTTS Babies?

Infants born after TTTS, particularly those treated with laser ablation, generally require neonatal intensive care due to the high incidence of preterm birth — more than 70 percent deliver before 34 weeks. Potential neonatal issues include cardiac dysfunction, hematologic abnormalities such as anemia or polycythemia, and growth discordance. Long-term follow-up is recommended to monitor for neurodevelopmental and cardiovascular sequelae. According to systematic reviews, survivors of TTTS have a higher risk of congenital heart disease compared with uncomplicated monochorionic twins.

What If One Baby Dies from TTTS?

When one twin dies in utero due to TTTS — corresponding to Quintero Stage V — the surviving twin is at acute risk of hemodynamic collapse, ischemic brain injury, and death. The vascular connections that enabled TTTS can cause sudden exsanguination of the survivor into the deceased twin’s circulation. Management after single fetal demise is expectant and focuses on close monitoring of the surviving twin for signs of anemia, cerebral injury, or preterm labor. Delivery is often considered once the survivor reaches a viable gestational age. In severe cases, selective fetocide may be performed to protect the remaining twin, but this is a last resort. The prognosis for a single survivor after Stage V is poor, with fewer than 20 percent surviving overall.

When Does TTTS Typically Develop and How Does It Progress?

TTTS most commonly presents between 16 and 26 weeks of gestation. The following timeline outlines the typical sequence of events from diagnosis through postnatal follow-up, based on current clinical protocols.

1. 16–26 weeks gestation: TTTS typically becomes detectable via ultrasound. Diagnosis is based on the oligo-polyhydramnios sequence and other sonographic criteria. Staging is performed immediately.
2. At diagnosis: Quintero staging (I–V) is assigned, and the patient is referred urgently to a fetal medicine center with laser expertise.
3. Days to weeks after diagnosis: Fetoscopic laser ablation is performed for Stages II through IV. Amnioreduction may be used for Stage I or as a temporizing measure.
4. Post-laser: Weekly ultrasound monitoring is conducted to detect recurrence, Twin Anemia-Polycythemia Sequence (TAPS), or selective intrauterine growth restriction (sIUGR).
5. Delivery: Planned delivery typically occurs between 34 and 37 weeks. Cesarean section is common due to fetal presentation and uterine distension.
6. After birth: Infants are admitted to the NICU for cardiac, hematologic, and growth assessment. Long-term neurodevelopmental follow-up is scheduled.

What Is Known and What Remains Uncertain About TTTS?

A considerable body of evidence supports the current understanding of TTTS, but several aspects of the condition remain the subject of ongoing research and clinical debate.

How Does TTTS Compare to Other Twin Pregnancy Complications?

TTTS is one of several complications that can affect monochorionic twin pregnancies, and it can sometimes mimic other conditions, including selective intrauterine growth restriction (sIUGR) and twin anemia-polycythemia sequence (TAPS). Accurate differentiation is critical because management strategies differ. TAPS, for example, involves a chronic transfusion imbalance that leads to anemia in one twin and polycythemia in the other, but without the severe fluid discrepancy that characterizes TTTS.

Unlike vanishing twin syndrome — in which one twin is lost early in the first trimester — TTTS involves ongoing blood exchange through the shared placenta and can present later in pregnancy. It is also distinct from complications seen in dichorionic twin pregnancies, which lack the vascular connections that give rise to TTTS. Understanding these distinctions is essential for appropriate diagnosis and counseling.

Where Can Families Find Reliable Information and Support for TTTS?

Expecting parents facing a TTTS diagnosis benefit from access to accurate medical information and emotional support. Several organizations and medical centers provide authoritative resources, helplines, and community networks.

“TTTS is a rare pregnancy condition affecting identical twins or other multiples.”

— Johns Hopkins Medicine

The Johns Hopkins Medicine TTTS overview provides a comprehensive, physician-reviewed summary of causes, diagnosis, and treatment options.

“TTTS is a rare but life-threatening condition that affects 10 to 15 percent of identical twins that share a placenta.”

— Twins Trust

The Twins Trust TTTS page offers a parent-focused perspective and UK-specific guidance for families.

“TTTS is a serious, progressive disorder. The twins do not have malformations, but one transfuses the other through abnormal or imbalanced blood vessel connections.”

— UCSF Fetal Treatment Center

The UCSF Fetal Treatment Center provides detailed clinical information on diagnosis, laser therapy, and outcomes from one of the leading fetal surgery programs in the United States.

Additional authoritative sources include the RCOG Green-top Guidelines on Multiple Pregnancy, the ACOG committee opinion on TTTS, and the National Organization for Rare Disorders (NORD) TTTS entry. For emotional and practical support, the TTTS Foundation offers a 24/7 helpline and connects families with peer support networks.

What Should Expecting Parents Know About TTTS?

For pregnant women carrying monochorionic twins, serial ultrasound screening starting at 16 weeks is the single most effective strategy for early detection of TTTS. If TTTS is diagnosed, immediate referral to a fetal therapy center with laser ablation capability offers the best chance of a favorable outcome. While the condition is serious, the majority of treated pregnancies result in at least one surviving infant, and many survivors go on to develop normally. For more detail on how TTTS is classified and managed, see Twin-to-Twin Transfusion Syndrome (TTTS): Comprehensive Overview.

Frequently Asked Questions About TTTS